ADAM ALLEN: Open Payments
NPI 1740549799 · SLIDELL, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$721 in 43 payments from 14 companies in 2025. Trend: 2023 $1,280 · 2024 $1,056 · 2025 $721
Food & beverage: $721
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $174 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $90 |
| Collegium Pharmaceutical, Inc. | 4 | $70 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| Noven Therapeutics, LLC | 2 | $42 |
| Corium, LLC | 3 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Tris Pharma Inc | 2 | $34 |
| Alkermes, Inc. | 2 | $33 |
Products named: VRAYLAR, CAPLYTA, Jornay PM, Auvelity, Qelbree, Xelstrym, Azstarys, FANAPT.
Industry payments across LA — which companies pay providers there.
